Market News

Latest financial and economic news and analysis

Zacks Investment Research News Agency
Yesterday•Zacks Investment Research
Stocks Medium Importance Neutral
Maplebear (CART) Misses Q2 Earnings Estimates

Maplebear (CART) Misses Q2 Earnings Estimates

Maplebear (CART) came out with quarterly earnings of $0.45 per share, missing the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.41 per share a year ago.

Related Symbols 1
CART CART
Source: Zacks Investment Research
Visit Source
Special Offer LiteFinance Start Trading
0 0 0
Read More
Comment
Zacks Investment Research News Agency
Yesterday•Zacks Investment Research
Stocks Medium Importance Neutral
The Trade Desk (TTD) Misses Q2 Earnings and Revenue Estimates

The Trade Desk (TTD) Misses Q2 Earnings and Revenue Estimates

The Trade Desk (TTD) came out with quarterly earnings of $0.34 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.41 per share a year ago.

Related Symbols 1
TTD TTD
Source: Zacks Investment Research
Visit Source
0 0 0
Read More
Comment
Zacks Investment Research News Agency
Yesterday•Zacks Investment Research
Stocks Medium Importance Neutral
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $0.34 per share a year ago.

Related Symbols 1
ARCT ARCT
Source: Zacks Investment Research
Visit Source
0 0 0
Read More
Comment
Zacks Investment Research News Agency
Yesterday•Zacks Investment Research
Stocks Medium Importance Neutral
Airbnb, Inc. (ABNB) Beats Q2 Earnings and Revenue Estimates

Airbnb, Inc. (ABNB) Beats Q2 Earnings and Revenue Estimates

Airbnb, Inc. (ABNB) came out with quarterly earnings of $1.37 per share, beating the Zacks Consensus Estimate of $1.2 per share. This compares to earnings of $1.03 per share a year ago.

Related Symbols 1
ABNB ABNB
Source: Zacks Investment Research
Visit Source
0 0 0
Read More
Comment
Zacks Investment Research News Agency
Yesterday•Zacks Investment Research
Stocks Medium Importance Neutral
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

Halozyme Therapeutics (HALO) came out with quarterly earnings of $2.28 per share, beating the Zacks Consensus Estimate of $1.82 per share. This compares to earnings of $1.54 per share a year ago.

Related Symbols 1
HALO HALO
Source: Zacks Investment Research
Visit Source
Special Offer LiteFinance Start Trading
0 0 0
Read More
Comment
Zacks Investment Research News Agency
Yesterday•Zacks Investment Research
Stocks Medium Importance Neutral
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates

Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.55 per share a year ago.

Related Symbols 1
JANX JANX
Source: Zacks Investment Research
Visit Source
0 0 0
Read More
Comment
Zacks Investment Research News Agency
Yesterday•Zacks Investment Research
Stocks Medium Importance Neutral
QuidelOrtho (QDEL) Surpasses Q2 Earnings and Revenue Estimates

QuidelOrtho (QDEL) Surpasses Q2 Earnings and Revenue Estimates

QuidelOrtho (QDEL) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.12 per share a year ago.

Related Symbols 1
QDEL QDEL
Source: Zacks Investment Research
Visit Source
Special Offer LiteFinance Start Trading
0 0 0
Read More
Comment
Zacks Investment Research News Agency
Yesterday•Zacks Investment Research
Stocks Medium Importance Neutral
Gen Digital (GEN) Beats Q1 Earnings and Revenue Estimates

Gen Digital (GEN) Beats Q1 Earnings and Revenue Estimates

Gen Digital (GEN) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.64 per share a year ago.

Related Symbols 1
GEN GEN
Source: Zacks Investment Research
Visit Source
0 0 0
Read More
Comment
Zacks Investment Research News Agency
Yesterday•Zacks Investment Research
Stocks Medium Importance Neutral
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates

10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates

10x Genomics (TXG) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.28 per share a year ago.

Related Symbols 1
TXG TXG
Source: Zacks Investment Research
Visit Source
Special Offer LiteFinance Start Trading
0 0 0
Read More
Comment
Proactive Investors News Agency
Yesterday•Proactive Investors
Stocks Medium Importance Neutral
UBS cuts Ocado target by a third as growth path stays clouded

UBS cuts Ocado target by a third as growth path stays clouded

UBS has cut its price target on Ocado Group PLC (LSE:OCDO) to 230p from 340p, a 34% reduction that reflects less confidence in the timing and scale of new contract wins rather than any change to its neutral rating. The shares closed at 212p on Wednesday, leaving barely 9% of implied upside.

Related Symbols 1
UBS UBS
Source: Proactive Investors
Visit Source
0 0 0
Read More
Comment
Proactive Investors News Agency
Yesterday•Proactive Investors
Stocks Medium Importance Neutral
Major boon predicted for Jersey Oil & Gas as bullish broker repeats Buy rating

Major boon predicted for Jersey Oil & Gas as bullish broker repeats Buy rating

Cavendish sees almost fivefold upside in Jersey Oil and Gas PLC (AIM:JOG, OTC:JYOGF) after regulators extended the Verbier licence, giving the partners more time to advance an integrated Greater Buchan Area development. The broker has repeated a Buy recommendation and 537p price target, representing 388% upside from the AIM-listed company's 110p share price.

Related Symbols 1
AIM AIM
Source: Proactive Investors
Visit Source
0 0 0
Read More
Comment
GlobeNewsWire News Agency
Yesterday•GlobeNewsWire
Stocks Medium Importance Neutral
B2Gold Reports Q2 2026 Results; Strong Operating Performance at the Fekola, Masbate, and Otjikoto Mines led to Higher than Expected Gold Production and Lower than Expected All-In Sustaining Costs; Menankoto Exploitation Permit Expected to be Issued in the

B2Gold Reports Q2 2026 Results; Strong Operating Performance at the Fekola, Masbate, and Otjikoto Mines led to Higher than Expected Gold Production and Lower than Expected All-In Sustaining Costs; Menankoto Exploitation Permit Expected to be Issued in the

VANCOUVER, British Columbia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G) (“B2Gold” or the “Company”) is pleased to announce its operational and financial results for the second quarter of 2026. All dollar figures are in United States dollars unless otherwise indicated.

Related Symbols 1
BTG BTG
Source: GlobeNewsWire
Visit Source
0 0 0
Read More
Comment